Miocrbot Medical® CEO to Discuss Recent FDA Clearance of the LIBERTY® Endovascular Robotic System
Microbot Medical Inc. (MBOT)
Last microbot medical inc. earnings: 11/14 03:34 pm
Check Earnings Report
US:NASDAQ Investor Relations:
microbotmedical.com/investors
Company Research
Source: GlobeNewswire
HINGHAM, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and manufacturer of the innovative LIBERTY® Endovascular Robotic System, announces that its Chief Executive Officer, Harel Gadot, will be interviewed on Benzinga All Access at 10:45am ET on Wednesday, September 24, 2025. The live interview can be viewed at: Benzinga All Access Live. Mr. Gadot will discuss the recent FDA clearance of Microbot Medical’s LIBERTY®, and how the Company has planned for commercialization in the U.S. as it redefines the peripheral endovascular space with LIBERTY®. On September 8, 2025, the Company announced it received FDA 510(k) clearance for commercialization of the LIBERTY® Endovascular Robotic System. About Microbot Medical Microbot Medical Inc. (NASDAQ: MBOT) is a breakthrough medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-us
Show less
Read more
Impact Snapshot
Event Time:
MBOT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBOT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBOT alerts
High impacting Microbot Medical Inc. news events
Weekly update
A roundup of the hottest topics
MBOT
News
- Microbot Medical (NASDAQ:MBOT) was upgraded by analysts at Roth Capital to a "strong-buy" rating. They now have a $5.50 price target on the stock.MarketBeat
- Microbot Medical (NASDAQ:MBOT) is now covered by analysts at Roth Capital. They set a "buy" rating on the stock.MarketBeat
- Microbot Medical (NASDAQ:MBOT) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Microbot Medical® Announces Emory University Hospital as the First Hospital in the World to Adopt the New LIBERTY® Endovascular Robotic SystemGlobeNewswire
- Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S. GlobeNewswire
MBOT
Sec Filings
- 11/26/25 - Form 8-K
- 11/19/25 - Form 424B3
- 11/19/25 - Form 424B3
- MBOT's page on the SEC website